Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)
Fast, easy summary view of NICE guidance on 'lower urinary tract symptoms in men'
NICE is unable to recommend the use in the NHS of tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia because no evidence submission was received from the manufacturer of the technology.
- Evidence Summary New Medicines: ESM18 Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: lower urinary tract symptoms in men
- None found
This page was last updated: 14 February 2014
Implementation tools and resources
- None available
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.